Goldman Sachs Group Inc Verastem, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	BUY	$0.39 - $0.71 $621 - $1,131	1,594 Added 8.45%	20,459 $8,000
Q1 2023 May 11, 2023	BUY	$0.39 - $0.71 $621 - $1,131	1,594 Added 8.45%	20,459 $8,000
Q4 2022 May 14, 2024	SELL	$0.33 - $10.44 $36,957 - $1.17 Million	-111,991 Reduced 85.58%	18,865 $7,000
Q4 2022 Feb 13, 2023	SELL	$0.33 - $10.44 $36,957 - $1.17 Million	-111,991 Reduced 85.58%	18,865 $7,000
Q3 2022 May 14, 2024	SELL	$0.92 - $11.16 $150,133 - $1.82 Million	-163,189 Reduced 55.5%	130,856 $111,000
Q3 2022 Nov 10, 2022	SELL	$0.92 - $11.16 $150,133 - $1.82 Million	-163,189 Reduced 55.5%	130,856 $0
Q2 2022 May 14, 2024	BUY	$1.02 - $1.83 $299,925 - $538,102	294,045 New	294,045 $341,000
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.83 $30,279 - $54,325	-29,686 Reduced 9.17%	294,045 $341,000
Q1 2022 May 16, 2022	BUY	$1.06 - $2.1 $50,638 - $100,321	47,772 Added 17.31%	323,731 $457,000
Q4 2021 Feb 14, 2022	SELL	$2.05 - $3.2 $726,809 - $1.13 Million	-354,541 Reduced 56.23%	275,959 $566,000
Q3 2021 Nov 10, 2021	BUY	$2.54 - $4.07 $1.6 Million - $2.57 Million	630,500 New	630,500 $1.94 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.09B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.